Free fatty acids induce ER stress and block antiviral activity of interferon alpha against hepatitis C virus in cell culture

Virology Journal

Volumn 9, Issue , 2012, Pages

  Gunduz, Feyza ^a   Aboulnasr, Fatma M ^a   Chandra, Partha K ^a   Hazari, Sidhartha ^a   Poat, Bret ^a   Baker, Darren P ^b   Balart, Luis A ^a   Dash, Srikanta ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b BIOGEN   (United States)

Author keywords

Endoplasmic reticulum stress; Free fatty acids; Hepatic steatosis; Hepatitis C virus; IFN alpha; Jak Stat signaling

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; FAT DROPLET; FATTY ACID; INTERFERON RECEPTOR; JANUS KINASE; LONG CHAIN FATTY ACID; OLEIC ACID; PALMITIC ACID; RECOMBINANT ALPHA2B INTERFERON; STAT1 PROTEIN; STAT2 PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; DOSE RESPONSE; DOWN REGULATION; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; FATTY LIVER; FLOW CYTOMETRY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIPID STORAGE; MICROFLUOROMETRY; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REPLICON; STAINING; VIRAL CLEARANCE; VIRUS REPLICATION;

CELL LINE; CYTOPHOTOMETRY; ENDOPLASMIC RETICULUM; FATTY ACIDS, NONESTERIFIED; FLOW CYTOMETRY; HEPACIVIRUS; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; LUCIFERASES; MICROSCOPY, ELECTRON; OXAZINES; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAINING AND LABELING; STRESS, PHYSIOLOGICAL;

HEPATITIS C VIRUS; RENILLA LUCIFERASE;

EID: 84864515284     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-143     Document Type: Article

References (52)

1. Hepatocellular carcinoma: recent trends in the United States. El-Serag HB, Gastroenterology 2004 127 27 34 10.1053/j.gastro.2004.09.013 (Pubitemid 39423367)
2. Global epidemiology of hepatitis C virus infection. Shepard CW, Finelli L, Alter MJ, Lancet Infect Dis 2006 5 558 567
3. Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. Deuffic S, Poynard T, Valleron AJ, J Viral Hepat 1999 6 411 413 10.1046/j.1365-2893.1999.00178.x 10607258 (Pubitemid 29470172)
4. Diagnosis, management and treatment of hepatitis C: an update. Ghany MG, Strader DB, Thomas DL, Seeff LB, Hepatology 2009 49 1335 1374 10.1002/hep.22759 19330875
5. Host factors and failure of interferon alpha treatment in hepatitis C virus. Gao B, Hong F, Radaeva S, Hepatology 2004 39 880 890 10.1002/hep.20139 15057887 (Pubitemid 38428923)
6. Role of obesity, insulin resistance and steatosis in hepatitis C virus infection. Puri P, Sanyal AJ, Clin Liver Dis 2006 10 703 819
7. Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Sanyal A, Liver Int 2011 31 23 28 21205134
8. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. Negro F, Clement S, J Viral Hepat 2009 16 681 688 10.1111/j.1365-2893.2009.01186.x 19732324
9. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Alberti A, Liver Int 2009 29 15 18 19207961
10. Interferon alpha, beta, gamma each inhibits hepatitis C virus replication at the levels of internal ribosome entry site mediated translation. Dash S, Prabhu R, Hazari S, Luo G, Bastian F, Garry RF, Zou W, Haque S, Joshi B, Regenstein FG, Thung SN, Liver Int 2005 25 1 15 10.1111/j.1478-3231.2005.01012.x 15698392 (Pubitemid 40298238)
11. Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus sub genomic replicons. Guo J, Zhu Q, Seeger C, J Virol 2003 77 10769 10779 10.1128/JVI.77.20.10769-10779.2003 14512527 (Pubitemid 37204270)
12. Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. Cheney IW, Lai VCH, Zhong W, Brodhag T, Dempsey S, Lim C, Hong Z, Lau JYN, Tam RC, J Virol 2002 76 11148 11154 10.1128/JVI.76.21.11148-11154.2002 12368359 (Pubitemid 35176233)
13. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. Vrolijk JM, Kaul A, Hanson BE, Lohmann V, Haagmans BL, Schalm SW, Bartenschalager R, J Virol Methods 2003 110 201 209 10.1016/S0166-0934(03)00134-4 12798249 (Pubitemid 36645265)
14. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. Wang C, Pflugheber J, Sumpter R, Sodora DL, Hui D, Sen G, Gale M, J Virol 2003 77 3898 3912 10.1128/JVI.77.7. 3898-3912.2003 12634350 (Pubitemid 36350931)
15. Abnormalities of lipid metabolisms in hepatitis C virus infection. Negro F, Gut 2010 59 1279 1287 10.1136/gut.2009.192732 20660700
16. Mechanisms of hepatitis C virus-related insulin resistance. Negro F, Clin Res Hepatol Gastroenterol 2011 35 358 363 10.1016/j.clinre.2011.01.011 21354385
17. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Walch MJ, Johnson JR, Richardson MM, Lipka GM, Clouston AD, Powell EE, Gut 2006 55 529 535 10.1136/gut.2005.069674 16299039
18. High body mass index is an independent risk factor for nonresponsive to antiviral treatment in chronic hepatitis C. Bressler BL, Guindi M, Tomlinson G, Heathcote J, Hepatology 2003 38 639 644 12939590 (Pubitemid 37052150)
19. Steatosis and liver cell apoptosis in chronic hepatitis C: A mechanism for increased liver injury. Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jansson JR, Powell EE, Hepatology 2004 39 1230 1238 10.1002/hep.20179 15122751 (Pubitemid 38569044)
20. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J, Clin Sci (Lond) 2004 106 635 643 10.1042/CS20030326 (Pubitemid 38797577)
21. Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. Hazari S, Chandra PK, Poat B, Datta S, Garry RF, Foster TP, Kousoulas G, Wakita T, Dash S, Virol J 2010 7 36 10.1186/1743-422X-7-36 20149251
22. O Conner J-E: A human hepatocellular in vitro model to investigate steotosis. Gomez-Lechon MJ, Donato MT, Martinez-Romero A, Jimenez N, Castell JV, Chem Biol Interact 2007 165 106 116 10.1016/j.cbi.2006.11.004 17188672 (Pubitemid 46072796)
23. Differential effect of oleic acid and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. Ricci M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, Bertolitti M, Banni S, Lenardo A, Carulli N, Loria P, J Gastroenterology Hepatol 2009 24 830 840 10.1111/j.1440-1746.2008.05733.x
24. Chronic palmitate but not the oleate exposure induces endoplasmic reticulum stress which may contribute to IRS-1 pancreatic b-cell apoptosis. Karaskov E, Scott C, Zhang L, Teodoro T, Ravazzola M, Volchuk A, Endocrinology 2005 147 3398 3407 (Pubitemid 43901131)
25. Potential impact of steatosis on cytochrome p450 enzymes of human hepatocytes isolated from fatty liver grafts. Donato MT, Lahoz A, Jimenez N, Perez G, Serralta A, Mir J, Castell JV, Gomez-Lechon MJ, Drug Metab Dispos 2006 34 1556 1562 10.1124/dmd.106.009670 16763015 (Pubitemid 44285398)
26. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ, J Hepatol 2003 39 978 983 10.1016/S0168-8278(03)00460-4 14642615 (Pubitemid 37523769)
27. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in 4 T1 metastatic breast cancer model. Bao L, Haque A, Jackson K, Hazari S, Moroz K, Jetley R, Dash S, Am J Pathol 2011 178 838 852 10.1016/j.ajpath.2010.10.029 21281816
28. Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. Chandra PK, Hazari S, Poat B, Gunduz F, Prabhu R, Liu G, Burioni R, Clementi M, Garry RF, Dash S, Virol J 2010 7 118 10.1186/1743-422X-7-118 20529250
29. Measuring antiviral activity of benzimidazole molecules that alters IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase. Liu S, Nelson CA, Xiao L, Lu L, Seth PP, Davis DR, Hagedorn CH, Antiviral Res 2011 89 54 63 10.1016/j.antiviral.2010.11.004 21075143
30. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Wei Y, Wang D, Topczewski F, Pagliassotti MJ, Am J Physiol Endocrinol Metab 2006 291 275 281 10.1152/ajpendo.00644.2005 (Pubitemid 44035286)
31. Endoplamsic reticulum stress links obesity, insulin action and type 2 diabetes. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun CZ, Glimcher LH, Hotamisligil GS, Science 2004 306 457 461 10.1126/science.1103160 15486293 (Pubitemid 39372439)
32. HCV genotypes in chronic hepatitis C and response to interferon. Kanai K, Kako M, Okamoto H, Lancet 1992 339 1543 1351217
33. Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to interferon therapy in chronic hepatitis C. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Ilotova V, Benhamou JP, Erlinger S, Hepatology 1995 22 1050 1056 7557850
34. Effect of treatment with peg interferon or interferon alpha 2b and ribavirin on steatosis in patients infected with hepatitis C. Poynard T, Ratziu V, McHutchinson J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J, Hepatology 2003 38 75 85 12829989 (Pubitemid 36775798)
35. Steatosis in chronic hepatitis C: relative contribution of obesity, diabetes mellitus and alcohol. Monto A, Alonzo J, Watson JJ, Grunfeld G, Wright TL, Hepatology 2001 36 729 736
36. Steatosis in chronic hepatitis C: why does it really matter? Asselah T, Rubbia-Brandt L, Marcellini P, Negro F, Gut 2005 55 123 130
37. Analysis of histopathological manifestation of chronic HCV infection with respect to virus genotype. Mihm S, Fayyazi A, Hartmann H, Ramodori G, Hepatology 1997 25 735 739 10.1002/hep.510250340 9049227 (Pubitemid 27106462)
38. Hepatitis C virus core protein and very low density lipoprotein secretion: a model of viral related steatosis. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C, FASEB J 2002 16 185 194 10.1096/fj.01-0396com 11818366 (Pubitemid 34113012)
39. Hellstrand K; DITTO-HCV Study Group: Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, Zeuzem S, Schalm SW, Verheij-Hart E, Negro F, Missale G, Neumann AU, J Viral Hepat 2007 14 29 35 17958640 (Pubitemid 46012358)
40. Effect of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Wu Y-J, Chen L-S, Qiang WG, Liver Int 2006 26 166 172 10.1111/j.1478-3231.2005.01219.x 16448454
41. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis C. Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, Vuturo O, Montalto G, Liver Int 2006 26 1119 1125 10.1111/j.1478-3231.2006.01347.x 17032413 (Pubitemid 44541753)
42. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S, Conrad A, Pockros PJ, McHutchison JG, J Hepatol 2004 40 484 490 15123364 (Pubitemid 38230851)
43. Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. Thomopoulos KC, Theocharis GJ, Tsamantas AC, Siagris D, Mimitropoulou D, Gogos CA, Labropoulou-Karatza C, Eur J Gastroenterol Hepatol 2005 27 149 153 (Pubitemid 40349527)
44. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Kapadia SB, Chisari FV, Proc Natl Acad Sci USA 2005 102 2561 2566 10.1073/pnas.0409834102 15699349 (Pubitemid 40279416)
45. Mechanisms of HCVs resistance to IFN-alpha in cell culture involves expression of functional IFN-alpha receptor 1. Datta S, Hazari S, Chandra PK, Samara M, Poat B, Gunduz F, Wimley WC, Hauser H, Koster M, Lamaze C, Balart L, Garry RF, Dash S, Virol J 2011 8 351 10.1186/1743-422X-8-351 21756311
46. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Liu J, HuangFu WC, Kumar KG, Qian J, Casey JP, Hamanaka RB, Grigoriadou C, Aldabe R, Diehl JA, Fuchs SY, Cell Host Microbe 2009 5 1 72 83 10.1016/j.chom.2008.11.008 19154989
47. The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor. Minakshi R, Padhan K, Rani M, Khan N, Ahmad F, Jameel S, PLoS One 2009 17 4 8342
48. Intrahepatic mRNA levels of type I interferon receptor and interferon stimulated genes in genotype 1b chronic hepatitis C. Taniguchi H, Iwasaki Y, Takahashi A, Shimomura H, Moriya A, Yu PC, Umeoka F, Fujioka S, Koide N, Shiratori Y, Intervirology 2007 50 32 39 10.1159/000096310 17164555 (Pubitemid 46005269)
49. Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection. Morita K, Tanaka K, Saito S, Kitamura T, Kondo M, Sakaguchi T, Morimoto M, Sekihara H, J Clin Gastroenterol 1998 26 135 140 10.1097/00004836-199803000-00010 9563926 (Pubitemid 28173095)
50. Type 1 interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. Fujiwara D, Hino K, Yamaguchi Y, Kubo Y, Yamashita S, Uchida K, Konishi T, Nakamura H, Korenaga M, Okuda M, Okita K, J Viral Hepat 2004 11 136 140 10.1046/j.1365-2893.2003.00477.x 14996348 (Pubitemid 38365764)
51. Expression of interferon-alpha/beta receptor protein in liver of patients with hepatitis C virus -related chronic liver disease. Meng XW, Chi BR, Chen LG, Zhang LL, Zhuang Y, Huang HY, Sun X, World J Gastroenterol 2005 11 3962 3965 15991303 (Pubitemid 41025257)
52. O'Brien TR; HALT-C Trial Group: Variants in Interferon-alpha pathway genes and response to pegylated interferon-alpha 2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C Antiviral Long-term treatment against Cirrhosis trial. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, Hepatology 2009 49 1847 1858 10.1002/hep.22877 19434718